Roth Capital analyst Joseph Pantginis trimmed his price target on Regeneron Pharma (NASDAQ: REGN) to $520.00 (from $555.00) but ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change FDA

Regeneron (REGN) PT Lifted to $523 at Leerink PartnersApril 4, 2016 6:21 AM Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III DataApril 1, 2016 11:52 AM Regeneron (REGN), Sanofi (SNY)Announce Two Dupilumab Phase 3s Met Primary Endpoint in Atopic DermatitisApril 1, 2016 6:57 AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis PatientsApril 1, 2016 1:00 AM